ÌÇÐÄVlog

Biography

E. Anders Kolb, MD is Director of the ¾Ã¾Ã¾Ã¾Ã¾Ã¾Ã¾Ã¾«Æ· Center for Cancer and Blood Disorders, Wilmington, Delaware, and Professor of Pediatrics, Sidney Kimmel Medical College at Thomas Jefferson University. Dr. Kolb is a national leader in the Children's Oncology Group (COG), chairing its Myeloid Disease Committee from 2012-2022, and serving on its Scientific Council. In addition, Dr. Kolb is a member of the FDA Oncologic Drug Advisory Committee's Pediatric Subcommittee and the National Heart, Lung and Blood Institute Bone Marrow Transplant Clinical Trials Network Data and Safety Monitoring Board. Dr. Kolb has proudly served as Co-Chair of the Leukemia & Lymphoma Society PedAL initiative. PedAL is a master clinical trial that will test simultaneously multiple targeted therapies for children who face a relapse of their acute leukemia. The study will take place at more than 200 sites worldwide. Dr. Kolb is certified by the American Board of Pediatrics and its sub-board in pediatric hematology/oncology. He completed pediatric residency training at St. Christopher's Hospital for Children and fellowship training in hematology/oncology in the Department of Pediatrics at Memorial Sloan-Kettering Cancer Center. Among his clinical and research interests are bone marrow transplantation, acute myeloid leukemia (AML), and drug development for children with leukemias. Dr. Kolb, continually funded by the National Institute of Health, has published more than 170 scientific manuscripts. He serves as the Principal Investigator on the ¾Ã¾Ã¾Ã¾Ã¾Ã¾Ã¾Ã¾«Æ· Children's Health System National Cancer Institute Community Oncology Research Program and the ¾Ã¾Ã¾Ã¾Ã¾Ã¾Ã¾Ã¾«Æ· Sickle Cell Center of Biomedical Research Excellence. Under his leadership, ¾Ã¾Ã¾Ã¾Ã¾Ã¾Ã¾Ã¾«Æ· has been consistently ranked among the top U.S. children's hospitals for pediatric oncology and hematology, exceeding national benchmarks for five-year cancer survival rates and bone marrow transplant survival rates.